DUBLIN--(BUSINESS WIRE)--The "Australia Non-Invasive Prenatal Testing Market 2025 - 2033" has been added to ResearchAndMarkets.com's offering.

The Australia Non-Invasive Prenatal Testing (NIPT) market, valued at USD 57.8 million in 2024, is expected to reach USD 83.3 million by 2033, expanding at a 4.1% CAGR from 2025 to 2033.

The report's scope encompasses a comprehensive research methodology, insights into market determinants, historical market growth from 2018 to 2024, and future projections. It evaluates the number of NIPT tests conducted with forecasts for eight years, offering a complete market potential and opportunity assessment.

The expansion of the Australian NIPT market is driven by several factors. A heightened awareness among healthcare providers and parents regarding early detection of genetic abnormalities has led to increased demand for NIPT. Initiatives aimed at educating these groups and the rise of hereditary genetic disorders further fuel this demand.

Technological innovations in genomic sequencing have enhanced the accessibility and affordability of NIPT, with more healthcare facilities adopting these advanced technologies, thereby improving reliability and efficiency. Government support has also played a crucial role. Regulatory frameworks designed to promote the adoption of NIPT have improved public trust and incentivized service providers to integrate these tests into their offerings, thus encouraging market growth.

The market report offers an exhaustive examination of the Australia NIPT market, including the latest industry data, historical market size from 2018-2024, and forecasts extending to 2033. It delves into industry situations, market demands, test volumes, revenues, and forecasts through 2033. The report also includes a comparative test analysis by companies, exploring reimbursement patterns and offering insights into the regulatory landscape in Australia.

Detailed analysis of trends such as collaboration deals, partnerships, mergers and acquisitions, venture capital investments, and licensing agreements are covered extensively. Additionally, the report includes a SWOT analysis, evaluating market drivers and challenges within the Australian context. Leading market players, assessed on business outlook and developments, are also profiled.

Prominent players in the Australia NIPT market include:

• Healius Limited
• Hoffmann-La Roche Ltd
• Illumina, Inc.
• Novacyt
• BGI Genomics
• Natera, Inc.
• Monash IVF Group
• Virtus Health
• Sonic Healthcare Limited
• Victorian Clinical Genetics Services Limited

Key Attributes:

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Australia Non-Invasive Prenatal Testing Volume and Forecast (2018 - 2033)

5. Australia Non-Invasive Prenatal Testing Market Size and Forecast (2018 - 2033)

6. Australia Non-Invasive Prenatal Testing Market Growth Drivers and Challenges

7. Non-Invasive Prenatal Testing Comparative Analysis

8. Reimbursement Environment of the Australia Non-Invasive Prenatal Testing Market

9. Regulation Framework of the Australia Non-Invasive Prenatal Testing Market

10. Major Deals and Agreements in the Non-Invasive Prenatal Testing Market

11. SWOT Analysis

12. Key Companies Analysis

• BGI Genomics
• F. Hoffmann-La Roche Ltd
• Healius Limited
• Illumina, Inc.
• Monash IVF Group
• Natera, Inc.
• Novacyt
• Sonic Healthcare Limited
• Victorian Clinical Genetics Services Limited
• Virtus Health

For more information about this report visit https://www.researchandmarkets.com/r/cdedbw

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900